Readnour Robin Shane has filed 27 insider transactions across 1 company since June 2023.
Most recent transaction: a grant/award of 20724 shares of AN2 Therapeutics, Inc. ($ANTX) on March 19, 2026.
Activity breakdown: 14 open-market purchases and 4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | A | Stock Option (right to buy) | 20724 | $0.00 | 20,724.0000 | 30,276,230 | 9999.99% | 0.07% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | D | Stock Option (right to buy) | 23742 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.08% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | A | Stock Option (right to buy) | 23742 | $0.00 | 23,742.0000 | 30,276,230 | 9999.99% | 0.08% |
| March 19, 2026 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | D | Stock Option (right to buy) | 20724 | $0.00 | 0.0000 | 30,276,230 | 100.00% | 0.07% |
| Feb. 20, 2026 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | A | Stock Option (Right to Buy) | 20400 | $0.00 | 20,400.0000 | 30,276,230 | 9999.99% | 0.07% |
| May 22, 2025 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | A | Stock Option (Right to Buy) | 19111 | $0.00 | 19,111.0000 | 29,828,227 | 9999.99% | 0.06% |
| Dec. 19, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | A | Common Stock | 9077 | $0.00 | 1,243,938.0000 | 29,841,169 | 0.74% | 0.03% |
| Dec. 10, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 5000 | $1.49 | 652,573.0000 | 29,841,169 | 0.77% | 0.02% |
| Dec. 10, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 5000 | $1.49 | 582,288.0000 | 29,841,169 | 0.87% | 0.02% |
| Dec. 9, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 18483 | $1.43 | 647,573.0000 | 29,841,169 | 2.94% | 0.06% |
| Dec. 9, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 12289 | $1.43 | 577,288.0000 | 29,841,169 | 2.18% | 0.04% |
| Dec. 6, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 6517 | $1.45 | 629,090.0000 | 29,841,169 | 1.05% | 0.02% |
| Dec. 6, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 12711 | $1.45 | 564,999.0000 | 29,841,169 | 2.30% | 0.04% |
| Nov. 27, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 25000 | $1.42 | 552,288.0000 | 29,841,169 | 4.74% | 0.08% |
| Nov. 26, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 12500 | $1.39 | 597,573.0000 | 29,841,169 | 2.14% | 0.04% |
| Nov. 26, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 12500 | $1.39 | 527,288.0000 | 29,841,169 | 2.43% | 0.04% |
| Nov. 27, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 25000 | $1.42 | 622,573.0000 | 29,841,169 | 4.18% | 0.08% |
| Nov. 19, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 75000 | $1.04 | 489,788.0000 | 29,841,169 | 18.08% | 0.25% |
| Nov. 20, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 25000 | $1.16 | 585,073.0000 | 29,841,169 | 4.46% | 0.08% |
| Nov. 20, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 25000 | $1.15 | 514,788.0000 | 29,841,169 | 5.10% | 0.08% |
| Nov. 19, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | P | Common Stock | 75000 | $1.03 | 560,073.0000 | 29,841,169 | 15.46% | 0.25% |
| June 19, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Not found | A | Stock Option (Right to Buy) | 64503 | $0.00 | 64,503.0000 | 23,600,107 | 9999.99% | 0.27% |
| Jan. 12, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Director | S | Common Stock | 719 | $21.91 | 485,073.0000 | 23,600,107 | 0.15% | 0.00% |
| Jan. 12, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Director | S | Common Stock | 706 | $21.92 | 414,788.0000 | 23,600,107 | 0.17% | 0.00% |
| Jan. 10, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Director | S | Common Stock | 1869 | $21.93 | 415,494.0000 | 23,600,107 | 0.45% | 0.01% |
| Jan. 10, 2024 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Director | S | Common Stock | 1800 | $21.92 | 485,792.0000 | 23,600,107 | 0.37% | 0.01% |
| June 7, 2023 | AN2 Therapeutics, Inc. | $ANTX | Readnour Robin Shane | Director | A | Stock Option (right to buy) | 23742 | $0.00 | 23,742.0000 | 0 | 9999.99% | 0.00% |